Transcription
Susan G. Komen for the CureResearch Grants – Fiscal Year 2009This slate of research grants was approved by Komen’s national board of directors onMarch 25, 2009. These grants will be funded upon the execution of grant agreementsbetween Komen and the grantee institutions.Promise GrantsThis exciting award mechanism provides substantial funding for multidisciplinary teams ofclinical and laboratory investigators to conduct a set of related studies addressing anoverarching issue of critical importance in breast cancer. Funding: Up to 7.5M (no morethan 1.5M per year) for up to 5 years.Targeting Death Receptors for the Treatment of Triple Negative Breast CancerCo-Investigators:Andres Forero, MDTong Zhou, MDUniversity of Alabama at BirminghamBirmingham, ALScientific Area: Targeted Therapies 6,420,821Comprehensive Biomarker Discovery Project for Bevacizumab in Breast CancerCo-Investigators:Bryan Schneider, MDDavid Flockhart, MD, PhDIndiana University, IndianapolisIndianapolis, INScientific Area: Diagnostic and Prognostic Biomarkers 5,825,618Therapy-relevant Stratification of Breast Cancer Patients: Integrating Pathology andBiomarker AnalysesCo-Investigators:Hallgeir Rui, MD, PhDEdith Mitchell, MDThomas Jefferson UniversityPhiladelphia, PAScientific Area: Targeted Therapies 6,676,115FY09 Research GrantsRev. 7/28/09Page 1 of 177
Pending Execution of Grant AgreementsDevelopment of novel early detection and prevention strategies for ER negative breastcancerCo-Investigators:Dihua Yu, MD, PhDM.D. Anderson Cancer Center, University of TexasHouston, TXVictoria Seewaldt, MD, PhDDuke UniversityDurham, NCScientific Area: Diagnostic and Prognostic Biomarkers 6,750,000Investigator Initiated ResearchThese grants seek to stimulate exploration of important issues and novel approaches thatwill lead to reductions in breast cancer incidence and/or mortality within the next decade.Funding: 200,000 per year for 2 to 3 years.Inhibition of Breast Cancer Cell Aggressiveness by CannabidiolSean McAllister, PhDCo-PI: Pierre-Yves Desprez, PhDCalifornia Pacific Medical CenterScientific Area: Targeted Therapies 593,713San Francisco, CABreast Cancer Risk Reduction in Primary Care Clinics: A Bilingual Intervention for Womenand PhysiciansCelia Kaplan, DrPHUniversity of California at San FranciscoSan Francisco, CAScientific Area: Nutritional, Behavioral and Lifestyle Prevention 599,803From Bench to Bedside: Treatment of Breast Cancer Brain Metastasis with 131I andRadiosensitizersIrene Wapnir, MDCo-PI: Michael Goris, PhDStanford University, School of MedicineStanford, CAScientific Area: Nonsystemic Therapies 600,000Induction of apoptosis of highly invasive breast cancer cells by novel small moleculeinhibitors of intracellular urokinase plasminogen activatorKermit Carraway, PhDCo-PI: Fredric Gorin, MD, PhDUniversity of California at Davis, School of MedicineDavis, CAScientific Area: Targeted Therapies 600,000FY09 Research GrantsRev. 07/28/09Page 2 of 177
Pending Execution of Grant AgreementsRestoration of MicroRNA-200c: a Novel Differentiation Therapy for Treatment of AggressiveBreast CancersJennifer Richer, PhDUniversity of Colorado Health Sciences CenterAurora, COScientific Area: Targeted Therapies 600,000Targeting the pro-inflammatory milieu of the involuting gland to suppress pregnancyassociated breast cancer metastasisPepper Schedin, PhDCo-PI: Virginia Borges, MDUniversity of Colorado Health Sciences CenterAurora, COScientific Area: Pathobiology 599,696In Situ Detection of Cancer Stem Cells to Predict Non-Nodal Metastasis in Breast CancerDavid Rimm, MD, PhDYale UniversityNew Haven, CTScientific Area: Diagnostic and Prognostic Biomarkers 600,000Cell Death Signaling in Endocrine ResponsivenessRobert Clarke, PhDCo-PI: Bassem Haddad, MDGeorgetown University, Lombardi Comprehensive Cancer CenterScientific Area: Endocrine Therapies 599,123Washington, DCDevelopment of Agonistic 4-1BB Aptamers to Enhance Vaccine-Induced Tumor ImmunityEli Gilboa, PhDUniversity of Miami, School of MedicineMiami, FLScientific Area: Immunotherapies 600,000Predicting Breast Cancer by Detection of Promoter Hypermethylation in Serum DNASusan Sturgeon, DrPHUniversity of MassachusettsAmherst, MAScientific Area: Diagnostic and Prognostic Biomarkers 236,171Functional consequence of deregulated HoxB9 expression in breast tumorsShyamala Maheswaran, PhDMassachusetts General HospitalCharlestown, MAScientific Area: Diagnostic and Prognostic Biomarkers 600,000FY09 Research GrantsRev. 07/28/09Page 3 of 177
Pending Execution of Grant AgreementsSystematic RNAi Knockdown and Systems Biology Approach Reveal Roles and Interactionsof Signaling Pathways in Mechanisms of Acquired Antiestrogen ResistanceToshihiro Shioda, MD, PhDMassachusetts General HospitalCharlestown, MAScientific Area: Endocrine Therapies 599,995Functional Metabolic Near-infrared Tomographic Optical Breast Imaging (TOBI) to MonitorResponse to Neoadjuvant Therapy in Breast CancerSteven Isakoff, MD, PhDMassachusetts General HospitalBoston, MAScientific Area: Diagnostic and Prognostic Biomarkers 599,842Plasma marker of oxidative stress and risk of breast cancer: a prospective studyHeather Eliassen, ScDBrigham and Women’s HospitalBoston, MAScientific Area: Epidemiology and Risk Assessment 587,903Lysosomal Associated Protein Transmembrane 4B (LAPTM4B), a novel drug resistance genein breast cancerAndrea Richardson, MD, PhDCo-PI: Zhigang Wang, MD, PhDDana-Farber Cancer InstituteBoston, MAScientific Area: Targeted Therapies 600,000Genetic variants and gene-environment interactions in relation to breast cancer incidence inAfrican-American womenJulie Palmer, ScDTrustees of Boston University, BUMCBoston, MAScientific Area: Epidemiology and Risk Assessment 598,000Evaluation of Low-dose Molecular Breast Imaging as a Screening Tool in Women withMammographically Dense Breasts and Increased Risk of Breast CancerDeborah Rhodes, MDMayo Clinic and Foundation, RochesterRochester, MNScientific Area: Diagnostic and Prognostic Biomarkers 599,558FY09 Research GrantsRev. 07/28/09Page 4 of 177
Pending Execution of Grant AgreementsA Phase I/II Trial of Short Course Pre-Operative Ritonavir in Breast CancerDavid Potter, MD, PhDUniversity of Minnesota at Twin CitiesMinneapolis, MNScientific Area: Targeted Therapies 600,000Whole Genome Profiling and Functional Genomics in Breast CancerMatthew Ellis, MD, PhDWashington University in St. Louis, School of MedicineScientific Area: Diagnostic and Prognostic Biomarkers 600,000St Louis, MOTbetaRIII/sTbetaRIII in the Diagnosis and Treatment of Breast CancerGerard Blobe, MD, PhDDuke University, School of MedicineScientific Area: Diagnostic and Prognostic Biomarkers 600,000Durham, NCMammary epithelial cell types as determinant of hypoxia responses in breast cancersJen-Tsan Chi, MD, PhDCo-PI: Jeffrey Marks, PhDDuke University Medical CenterDurham, NCScientific Area: Pathobiology 600,000Development of Molecularly Targeted Therapeutics for Osteolytic Bone MetastasisRakesh Singh, PhDCo-PI: Dong Wang, PhDUniversity of Nebraska Medical Center, Eppley Cancer CenterOmaha, NEScientific Area: Targeted Therapies 600,000Analysis of NR1D1, a circadian rhythm metabolic regulator required for breast cancer cellsurvivalDouglas Conklin, PhDState University of New York at AlbanyRensselaer, NYScientific Area: Targeted Therapies 246,800Determining Role of EMT in Metastatic Progression of Human Breast Cancer.Jihe Zhao, MD, PhDAlbany Medical CollegeScientific Area: Pathobiology 600,000FY09 Research GrantsRev. 07/28/09Albany, NYPage 5 of 177
Pending Execution of Grant AgreementsRole of CAV1 in Suppressing Estrogen-Hypersensitivity, DCIS, and Breast CancerProgressionMichael Lisanti, MD, PhDCo-PI: Federica Sotgia, PhDThomas Jefferson UniversityPhiladelphia, PAScientific Area: Endocrine Therapies 480,000Sphingosine Kinase Inhibitors as Anti-Breast Cancer Therapeutic AgentsJong Yun, PhDPennsylvania State University, College of MedicineScientific Area: Targeted Therapies 400,000P-Rex1 in ErbB Signaling and Breast CancerMarcelo Kazanietz, PhDUniversity of Pennsylvania, School of MedicineScientific Area: Diagnostic and Prognostic Biomarkers 600,000Hershey, PAPhiladelphia, PAReal Time Assessment of Self-Reporting Chemotherapeutics for Targeted Treatment ofMetastatic Breast CancerJames McIntyre, PhDCo-PI: Darryl Bornhop, PhDVanderbilt University, School of MedicineNashville, TNScientific Area: Localized Chemotherapies 600,000Role of PELP1 in local estrogen synthesis and breast cancer progressionRatna Vadlamudi, PhDCo-PI: Rajeshwar Tekmal, PhDUniversity of Texas Health Science CenterScientific Area: Endocrine Therapies 600,000San Antonio, TXImproving Breast Cancer Outcomes in Older Women through More Effective Use ofScreening MammographyPamela Vacek, PhDUniversity of VermontBurlington, VTScientific Area: Nutritional, Behavioral and Lifestyle Prevention 382,262FY09 Research GrantsRev. 07/28/09Page 6 of 177
Pending Execution of Grant AgreementsCrosstalks among Stat3, PR and ErbB-2: a novel biomarker and tool for a new therapyagainst breast cancer in Latin American womenPatricia Elizalde, PhDInstitute of Biology and Experimental MedicineBuenos Aires, ArgentinaScientific Area: Pathobiology 600,000Career Catalyst ResearchThis award mechanism provides unique opportunities for scientists in the early stages oftheir career to further their research independence by providing support for researchexploring important issues and novel approaches that will lead to substantial progress inbreast cancer research and reductions in breast cancer incidence and/or mortality withinthe next decade. Funding: 300,000 for 2 years and a performance-based option for a 150,000 3rd year.Nucleotide variation in the prolactin receptor and its agonists and breast cancer riskShehnaz Hussain, PhDUniversity of California at Los AngelesLos Angeles, CAScientific Area: Epidemiology and Risk Assessment 299,912Preclinical Fluorescence Lifetime Imaging System For Early Detection of Breast Tumors InvivoV. Krishnan Ramanujan, PhDCedars Sinai Medical CenterLos Angeles, CAScientific Area: Diagnostic and Prognostic Biomarkers 299,919Regulation of ERRgamma in endocrine resistant breast cancer by the ERK pathwayRebecca Riggins, PhDGeorgetown UniversityWashington, DCScientific Area: Endocrine Therapies 449,112Targeting Myeloid Derived Suppressor Cells and Regulatory T Cell to Improve the Efficacy ofAnti-tumor Vaccine in a Spontaneous Model of Mammary CarcinomaPaolo Serafini, PhDUniversity of Miami, School of MedicineMiami, FLScientific Area: Immunotherapies 450,000FY09 Research GrantsRev. 07/28/09Page 7 of 177
Pending Execution of Grant AgreementsNanocarrier-based Targeted Chemotherapy for Improved Drug Delivery in Locally AdvancedBreast CancerMark Cohen, MDUniversity of Kansas Medical CenterKansas City, KSScientific Area: Nonsystemic Therapies 450,000Physiologic modeling of common PI3-kinase pathway mutations in human breast epithelialcells to develop mutant-specific targeted therapiesJosh Lauring, MD, PhDJohns Hopkins University, Kimmel Cancer CenterBaltimore, MDScientific Area: Targeted Therapies 450,000Developing Non-Invasive, in vivo Biomarkers to Guide Antiangiogenic Therapy in BreastCancer using MRIArvind Pathak, PhDJohns Hopkins University, School of MedicineBaltimore, MDScientific Area: Diagnostic and Prognostic Biomarkers 450,000Proteomic Identification and Reversal of Mechanisms of Herceptin Resistance in Her2/neuPositive Breast CancerRon Bose, MD, PhDWashington University in St. Louis, School of MedicineSt. Louis, MOScientific Area: Targeted Therapies 450,000An Integrated Genomic Analysis of the Invasive Breast Cancer Risk Associated with LobularCarcinoma in SituTari King, MDMemorial Sloan-Kettering Cancer CenterNew York, NYScientific Area: Diagnostic and Prognostic Biomarkers 299,999Breast Adipose Bioactivates Vitamin D and Contributes to Cancer PreventionGlendon Zinser, PhDUniversity of CincinnatiCincinnati, OHScientific Area: Pathobiology 381,250FY09 Research GrantsRev. 07/28/09Page 8 of 177
Pending Execution of Grant AgreementsAutoantibody Profiling As a Novel Method for Early and Personalized Diagnosis for BreastCancerKristi Egland, PhDSanford Research, University of South DakotaSioux Falls, SDScientific Area: Diagnostic and Prognostic Biomarkers 450,000A Functional Genomic Approach to Discovery of Breast Cancer Therapeutic TargetsThomas Westbrook, PhDBaylor College of MedicineHouston, TXScientific Area: Pathobiology 450,000DNA Damage as a Biomarker of Risk of Breast CancerIsabelle Bedrosian, MDM.D. Anderson Cancer Center, University of TexasScientific Area: Diagnostic and Prognostic Biomarkers 296,966Houston, TXSphingosine Kinase 1 as a New Target for Systemic Therapy against Breast Cancer –Development and Characterization of Novel Sphingosine Kinase 1 InhibitorKazuaki Takabe, MD, PhDVirginia Commonwealth UniversityRichmond, VAScientific Area: Targeted Therapies 449,556Career Catalyst in Disparities ResearchThis mechanism, new in FY09, provides a unique opportunity for scientists in the earlystages of their career, particularly scientists from populations affected by disparities inbreast cancer outcomes, to achieve research independence. Funding: 300,000 for 2 yearsand a performance-based option for a 150,000 3rd year.Breast Cancer in African American Women: DNA Methylation Studies in Basal-like, HER2 ,and Luminal A and B SubtypesTheresa Swift-Scanlan, PhDUniversity of North Carolina at Chapel HillChapel Hill, NCScientific Area: Diagnostic and Prognostic Biomarkers 450,000Development of Proteomic Signatures of Risk to Estrogen-Independent Breast CancerCatherine Drendall, PhDDuke University Medical CenterDurham, NCScientific Area: Chemoprevention 450,000FY09 Research GrantsRev. 07/28/09Page 9 of 177
Pending Execution of Grant AgreementsSearch for novel breast cancer susceptibility genes in pedigrees of African ancestryHeather Ochs-Balcom, PhDState University of New YorkBuffalo, NYScientific Area: Epidemiology and Risk Assessment 431,395Ethnic differences in the mutational status of the PI3K pathway and breast cancer outcomeAbenaa Brewster, MDM.D. Anderson Cancer Center, University of TexasHouston, TXScientific Area: Diagnostic and Prognostic Biomarkers 444,043Chemotherapy Resistance in Hispanic and African American PatientsAna Gonzalez-Angulo, MDM.D. Anderson Cancer Center, University of TexasScientific Area: Targeted Therapies 446,850Houston, TXPostdoctoral FellowshipThis continuing mechanism supports training for investigators early in their career and seeksto attract new scientists into careers in breast cancer research. Funding: 60,000 per yearfor 2 years and a performance-based option for a 60,000 3rd year.PDF—Basic ResearchDetermining the significance of the AKT(E17K) mutation in human breast cancerMentor: John Carpten, PhDFellow: Bodour Salhia, PhDTranslational Genomics Research Institute (TGen)Phoenix, AZScientific Area: Pathobiology 180,000Noncoding RNA, Polycomb and Breast Cancer ProgressionMentor: Howard Chang, MD, PhDFellow: Miao-Chih Tsai, PhDStanford University, School of MedicineScientific Area: Diagnostic and Prognostic Biomarkers 180,000Stanford, CATargeting Therapy-Resistant Tumor Vessels and Preventing Tumor RecurrenceMentor: Erkki Ruoslahti, PhDFellow: Lise Roth, PhDBurnham Institute for Medical ResearchSanta Barbara, CAScientific Area: Targeted Therapies 180,000FY09 Research GrantsRev. 07/28/09Page 10 of 177
Pending Execution of Grant AgreementsA novel epigenetic mark in breast cancerMentor: Jessica Tyler, PhDFellow: Chandrima Das, PhDUniversity of Colorado, Health Sciences CenterScientific Area: Diagnostic and Prognostic Biomarkers 180,000Identification of Small Molecule Transporters Essential to Breast CancerMentor: David Sabatini, PhDFellow: Richard Possemato, PhDWhitehead Institute for Biomedical Research, MITScientific Area: Targeted Therapies 180,000Aurora, COCambridge, MAUnderstanding Breast Cancer Risk Conferred by the FGFR2 Single NucleotidePolymorphismsMentors: James Iglehart, PhD and Alexander Miron, PhDFellow: Yelena Wetherill, PhDDana-Farber Cancer InstituteScientific Area: Epidemiology and Risk Assessment 180,000p63-regulated micro-RNAs in human breast cancerMentor: Leif Ellisen, PhDFellow: Benjamin Ory, PhDMassachusetts General HospitalScientific Area: Pathobiology 180,000Optimizing the Penetration of Nanoparticles in Breast TumorsMentor: Rekesh Jain, PhDFellow: Triantafyllos Stylianopoulos, PhDMassachusetts General HospitalScientific Area: Nonsystemic Therapies 180,000Boston, MABoston, MABoston, MAInfluence of Cancer Stem Cell on Non-stem Cancer Cell: Growth, Metastasis and StemnessMentor: Robert Weinberg, PhDFellow: Hua Jung Li, PhDWhitehead Institute for Biomedical Research, MITCambridge, MAScientific Area: Pathobiology 180,000FY09 Research GrantsRev. 07/28/09Page 11 of 177
Pending Execution of Grant AgreementsTargeting Wnt signaling pathway for breast cancer therapyMentor: Gregory Verdine, PhDFellow: Johannes Yeh, PhDHarvard UniversityScientific Area: Targeted Therapies 180,000Cambridge, MAInvestigating the mechanism of regulation of HOXA5 and consequences of its loss in breastcancerMentor: Josh Lauring, MD, PhDFellow: Xiaohui Liang, MD, PhDJohns Hopkins University, Kimmel Cancer CenterBaltimore, MDScientific Area: Pathobiology 180,000Role of p68 RNA helicase in the growth of breast epithelial cellsMentor: Jason Weber, PhDFellow: Anthony Saporita, PhDWashington University in St. Louis, School of MedicineScientific Area: Pathobiology 180,000Saint Louis, MOEffect of Matrix Compliance and Mechanical Tension on Fibrosis of the BreastMentor: Celeste Nelson, PhDFellow: Esther Gomez, PhDPrinceton UniversityPrinceton, NJScientific Area: Pathobiology 180,000Functional Status of Autophagy in Tumors as a Determinant in the Treatment of BreastCancerMentor: Vassiliki Karantza-Wadsworth, MD, PhDFellow: Ning Chen, PhDRobert Wood Johnson Medical SchoolNew Brunswick, NJScientific Area: Pathobiology 180,000Role of Alternative Splicing in Mammary Epithelial Cell TransformationMentor: Adrian Krainer, PhDFellow: Olga Anczukow-Camarda, PhDCold Spring Harbor LaboratoryCold Spring Harbor, NYScientific Area: Pathobiology 180,000FY09 Research GrantsRev. 07/28/09Page 12 of 177
Pending Execution of Grant AgreementsTGF-alpha: A key molecule in basal breast cancer?Mentor: Paraic Kenny, PhDFellow: Orsolya Giricz, PhDAlbert Einstein College of Medicine at Yeshiva UniversityScientific Area: Pathobiology 180,000The Role of MiRNAs in Mediating Resistance to Taxol Mentor: Susan Horwitz, PhDFellow: Lingling Liu, PhDAlbert Einstein College of Medicine at Yeshiva UniversityScientific Area: Diagnostic and Prognostic Biomarkers 180,000Bronx, NYBronx, NYRole and mechanism of chemokine RANTES in immunity against breast cancerMentor: Xiaojing Ma, MD, PhDFellow: Yan Zhang, PhDCornell University, Weill Medical CollegeNew York, NYScientific Area: Immunotherapies 180,000Pre-clinical development of tumor specific Hsp70 inhibitors in breast cancerMentor: Gabriela Chiosis, PhDFellow: Tony Taldone, PhDMemorial Sloan-Kettering Cancer CenterScientific Area: Targeted Therapies 180,000New York, NYPaxillin regulates matrix metalloproteinase trafficking/recycling and breast cancer cellinvasion in three-dimensional microenvironmentsMentor: Christopher Turner, PhDFellow: Nicholas Deakin, PhDState University of New York, Upstate Medical UniversitySyracuse, NYScientific Area: Pathobiology 180,000Tumor-derived Autophagosomes as a Novel Vaccine in Breast CancerMentor: Hong-Ming Hu, PhDFellow: Yuhuan Li, PhDProvidence Portland Medical CenterScientific Area: Targeted Therapies 180,000FY09 Research GrantsRev. 07/28/09Portland, ORPage 13 of 177
Pending Execution of Grant AgreementsBRCA1 Ubiquitin E3 Ligase Activity in DNA Damage Repair and Breast Cancer SuppressionMentor: Roger Greenberg, MD, PhDFellow: Yinggun Wang, PhDUniversity of Pennsylvania
Andres Forero, MD . Tong Zhou, MD . University of Alabama at Birmingham Birmingham, AL . . Co-PI: Fredric Gorin, MD, PhD . University of California at Davis, School of Medicine Davis, CA . Steven Isakoff, MD, PhD . Massachusetts General Hospital Boston, MA .
